Latest Articles

Publication Date
Anti-NRP1 peptide-engineered ROS/pH dual-responsive nanoparticles for Alpelisib delivery regulate Sema3A-NRP1/PI3K-AKT signaling to balance oxidative stress and inhibit angiogenesis in endometriosis.

Endometriosis progression is driven by oxidative stress and excessive angiogenesis within an inflammatory microenvironment. To overcome these challenges, we designed ROS/pH dual-responsive Alpelisib-loaded nanoparticles (Alp@TAT-AT7-NPs) functionalized with an anti-NRP1 peptide …

Published: June 6, 2026, midnight
MGST3 Promotes Endometriosis Progression by Suppressing Ferroptosis.

Endometriosis (EMs) is characterized by dysregulated persistence and enhanced invasiveness of ectopic endometrial cells. Current treatment strategies remain limited by high recurrence rates and considerable adverse effects. Although iron overload …

Published: June 3, 2026, midnight
UM research team identifies novel targeted therapy for endometrial cancer - University of Macau

UM research team identifies novel targeted therapy for endometrial cancer University of Macau

Published: May 13, 2026, 3:13 a.m.
FGFR2-responsive self-assembled hydrogel releases its inhibitor to suppress the progression of endometriosis.

Fibroblast growth factor receptor 2 (FGFR2) has emerged as a highly promising therapeutic target due to its critical role in the pathogenesis and progression of endometriosis. To date, a variety …

Published: May 9, 2026, midnight
Macrophage membrane-biomimetic nanovehicles delivering amygdalin halt pyroptosis propagation and alleviate endometriosis-associated neuropathic pain.

The clinical management of endometriosis encounters a significant obstacle: existing therapies inadequately address both the inhibition of ectopic lesion proliferation and the mitigation of the neuroinflammation associated with chronic pain. …

Published: April 20, 2026, midnight
Autophagy and Lysosomal Dysregulation in Endometriosis: Therapeutic Opportunities and Molecular Insights.

Published: March 17, 2026, midnight
2-Deoxyglucose dendrimer-enabled niclosamide delivery to FRβ-expressing macrophages alleviates endometriosis progression and associated hyperalgesia.

Endometriosis is a chronic, incurable disease. Due to limited efficacy, high recurrence rates, and serious side effects of current treatments, development of new, targeted, non-hormonal therapies is urgently needed. We …

Published: Feb. 12, 2026, midnight
Copper-Targeted Therapy in Experimental Endometriosis: Effects of Ammonium Tetrathiomolybdate on Markers of the Interconnected Processes of Inflammation, Innervation, and Fibrogenesis.

Endometriosis (EDT) is a chronic, estrogen-dependent disease characterized by inflammation, fibrosis, pelvic pain, and infertility. Current therapies show limited long-term efficacy and adverse effects, underscoring the need for novel therapeutic …

Published: Jan. 22, 2026, midnight
Transcriptomic landscape of coexisting ovarian clear cell carcinoma and endometriosis: Insights into malignant transformation.

This study investigateted the malignant transformation of endometriosis (EMS) into ovarian clear cell carcinoma (OCCC) using spatial transcriptomics and single-cell RNA sequencing (scRNA-seq) integration. Tissues with coexisting EMS and OCCC …

Published: Jan. 7, 2026, midnight
Research Advances in the Endometriotic Microenvironment: Synergistic Immune-Inflammatory-Angiogenic Interactions and their Therapeutic Translation.

Published: Dec. 29, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!